Pediatric Medulloblastoma â€“ Update on Molecular Classification Driving Targeted Therapies by Ruth-Mary DeSouza et al.
REVIEW ARTICLE
published: 22 July 2014
doi: 10.3389/fonc.2014.00176
Pediatric medulloblastoma – update on molecular
classification driving targeted therapies
Ruth-Mary DeSouza1, Benjamin R.T. Jones2, Stephen P. Lowis3 and Kathreena M. Kurian4*
1 Neurosurgery, King’s College Hospital London, London, UK
2 Royal Bolton Hospital, Bolton, UK
3 BMT/Oncology, University of Bristol, Bristol, UK
4 Brain Tumour Group, Institute of Clinical Neuroscience, University of Bristol, Bristol, UK
Edited by:
Arnab Chakravarti, The Ohio State
University Medical Center, USA
Reviewed by:
Kamalakannan Palanichamy, The Ohio
State University Medical Center, USA
Timothy A. Chan, Memorial Sloan
Kettering Cancer Center, USA
*Correspondence:
Kathreena M. Kurian, Department of
Neuropathology, Southmead
Hospital, Southmead Road, Bristol
BS10 5NB, UK
e-mail: kathreena.kurian@nbt.nhs.uk
As advances in the molecular and genetic profiling of pediatric medulloblastoma evolve,
associations with prognosis and treatment are found (prognostic and predictive biomark-
ers) and research is directed at molecular therapies. Medulloblastoma typically affects
young patients, where the implications of any treatment on the developing brain must be
carefully considered. The aim of this article is to provide a clear comprehensible update
on the role molecular profiling and subgroups in pediatric medulloblastoma as it is likely
to contribute significantly toward prognostication. Knowledge of this classification is of
particular interest because there are new molecular therapies targeting the Shh subgroup
of medulloblastomas.
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INTRODUCTION
Brain tumors are the most common solid malignancies in chil-
dren, and among these medulloblastoma is the most frequent (1).
The incidence of medulloblastoma is higher in males and higher
in early childhood, with almost half occurring before the age of
5 (1). At least 75% of childhood medulloblastomas arise in the
cerebellar vermis, and project into the fourth ventricle, with the
remainder involving the cerebellar hemispheres (see Figure 1) (1).
Spread may be via CSF and present in up to one-third of cases at
presentation (2).
The clinical features of medulloblastoma, as with other poste-
rior fossa pathology, can be difficult to detect initially in young
children, sometimes leading to a delayed diagnosis (3). Symptoms
include headache, general malaise, failure to feed, vomiting, clum-
siness, and other presentations that mimic common and benign
childhood pathologies seen in primary care (4). Typically, the
treatment strategies for medulloblastoma are threefold: maximal
safe resection (plus/minus CSF diversion), neuraxis radiotherapy,
and chemotherapy (4).
Survival in children with medulloblastoma has improved over
the last 20 years, and the quality of life in medulloblastoma sur-
vivors has been evaluated in terms of physical and non-physical
(5). Physical impairments include neurological deficits, secondary
malignancy, and endocrine dysfunction, whereas non-physical
deficits include cognitive difficulties and psychological and social
problems (6). The effect of these problems can be far reach-
ing, affecting employment and family life (7–9). Many long-term
sequelae are secondary to radiotherapy and one of the goals of
modern therapy is to minimize or avoid radiotherapy (7–9).
CLINICAL CLASSIFICATION
Medulloblastoma was classified clinically by Chang in 1969
based on the size and invasiveness of the tumor as determined
intra-operatively and on the presence of metastases (10). The
Chang system is no longer used, although elements of it form
the current clinical risk stratification of medulloblastoma (10).
Currently, medulloblastoma is classified clinically into high risk
and standard (average) risk, which is summarized in Table 1. The
factors contributing to this classification are solely clinical – age,
metastases, and resection (3). Age is a key factor, which may reflect
in part the aggressive natural history of tumors in the under-
three age group and also reflect the limitations and side effects of
therapy (3).
HISTOLOGICAL CLASSIFICATION
The World Health Organisation (WHO) classification system 2007
for medulloblastomas uses histology to classify medulloblastomas,
which can be considered three major groups including the classic
subtype; desmoplastic/nodular/medulloblastoma with extensive
nodularity (MBEN) subtypes; and large cell/anaplastic medul-
loblastoma subtypes (Figures 1 and 2). Classic medulloblastoma
represents the most common histological subtype (66%) (1), and
is composed of sheets of densely packed small round blue cells
(basophilic) with a high nuclear to cytoplasmic ratio, mitotic and
apoptotic activity, and may occur in the midline (1).
Desmoplastic/nodular medulloblastomas/MBEN (15%) typ-
ically carry a favorable prognosis, and may arise laterally in
a cerebellar hemisphere (1, 6). Desmoplastic medulloblastomas
also comprise small round blue tumor cells, but typically harbor
reticulin-free “pale islands” within a reticulin-rich stroma, which
are often immunopositive for synaptophysin indicating neuronal
differentiation (1, 4, 6). Anaplastic medulloblastomas (15%) are
characterized by marked nuclear pleomorphism, nuclear mold-
ing, and cell–cell wrapping (1) and the large cell variant (2–4%)
displays a monomorphous population of large cells whose nuclei
exhibit prominent nucleoli (1, 7). Both variants are characterized
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FIGURE 1 | MRI of head showing sagittal and horizontal views. Sagittal
view shows a midline posterior fossa medulloblastoma with intermediate
signal intensity. There is an obstruction to the flow of CSF, marked
hydrocephalus, and edema. Horizontal view shows a homogenous
enhancing medulloblastoma arising from the right cerebellar hemisphere
with displacement of the vermis.
Table 1 | Established prognostic variables accepted by the North
American Children’s Oncology Group (COG) and the SIOP
(International Society of Pediatric Oncology) Group.
Risk classification Characteristics
Standard-risk tumor ≥3 years of age without evidence of metastatic
spread and having ≤1.5 cm2 (maximum cross-
sectional area) of residual disease after surgery
High-risk tumor ≥3 years of age with evidence of CSF spread
(M1–M3) and/or those with less complete
resection (≥1.5 cm2) or <3 years of age at diagnosis
by a very high proliferative activity, abundant apoptosis, and a
much poorer prognosis (1, 11, 12).
The majority of medulloblastomas exhibit neuronal differen-
tiation in the form of immunoreactivity to synaptophysin and
some also display focal glial differentiation (Glial fibrillary acidic
protein (GFAP) immunopositivity) (1, 7, 8). Rare examples show
myogenic differentiation (medullomyoblastoma) or melanotic
differentiation (1, 7, 8).
MOLECULAR SUBGROUPS
More recently a consensus conference in Boston in 2010 sup-
ported classification of four main subgroups of medulloblastomas
based on the molecular profiling (7, 8, 13–17) (Figure 3). The
Wnt and Shh groups were named after the predominant sig-
naling pathways thought to be affected in their pathogenesis.
Less is known currently regarding the pathogenesis of groups 3
(tending to harbor MYC amplification) and 4 (tending to have
isochromosome 17q) and therefore generic names were chosen
until it is better understood (8). The Shh group has become of
increasing interest because of the availability and temporary suc-
cess of small molecule inhibitors to smoothened (SMO), which
is part of the Shh pathway. All four groups show relatively dis-
tinct variation in demographics, histology, genetic profile, and
FIGURE 2 | Graph showing the age distribution for different subgroups
of medulloblastoma adapted from Ref. (8).
clinical outcome (8). For a detailed comprehensive review on the
molecular subgroups of medulloblastoma, see the consensus paper
by Taylor et al. (5).
Wnt MEDULLOBLASTOMAS
Wnt tumors are thought to be the rarest subgroup of medul-
loblastoma, accounting for 11% (9), but they have probably been
the most studied and have a very good long-term prognosis with
overall survivals reaching 90% (18) (Figure 4). Wnt tumors also
show a specific age distribution being almost absent in infants
(aged <4 years) (see Figure 2) but predominantly affecting chil-
dren with a peak incidence of 10–12 years (see Figure 2) (9).
Wingless (Wnt) is a family of growth factor receptors that are
involved in embryogenesis and also in cell–cell control mecha-
nisms (9). Wnt tumors are thought to arise from mossy-fiber
neuron precursors, which may be involved in the formation of
synapses in the developing cerebellum (19). The majority of Wnt
medulloblastomas show classic histology, however rarely, they are
phenotypically large cell/anaplastic (1) and may remarkably retain
their relatively good prognosis with this phenotype (14). Molecu-
lar analysis of sporadic Wnt medulloblastomas commonly shows
CTNNB1 mutations, which encode β-catenin (see Figure 1) (14).
Moreover, germline mutations of the Wnt pathway inhibitor APC
predispose to Turcot syndrome in which medulloblastomas may
occur (7). Other less common mutations are found in sporadic
medulloblastomas, including APC, AXIN1, and AXIN2, which are
also keys to this pathway (14). A recent paper has also identi-
fied mutations in the RNA helicase DDX3X, which potentiates
transactivation of a TCF promoter, which is further downstream
(15). Most mutations result in over-activation of the Wnt signal-
ing pathway with increased nuclear (as opposed to cytoplasmic)
immunohistochemical staining for β-catenin, which can be rel-
atively easily identified by neuropathologists (15). Stimulation
of Wnt signaling results in nuclear accumulation of β-catenin
which complexes to TCF-4/lef-1 and functions in cell division
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FIGURE 3 | Histology showing (A) Classic medulloblastoma with nuclear β-catenin immunostaining; (B) Nodular medulloblastoma with cytoplasmic
β-catenin immunostaining; (C) Anaplastic medulloblastoma with cytoplasmic β-catenin immunostaining.
and proliferation (transcribes c-myc and cyclin D1), breakdown
of the extracellular matrix, as well as cell–cell adhesion (20).
Interaction between the PI3K/Akt and Wnt pathways occurs
in medulloblastomas and this appears to be crucial for tumor
survival (20).
Wnt medulloblastomas appear to be associated with the loss of
chromosome 6 and interestingly, they rarely express chromosome
17 aberrations which are the most common chromosomal alter-
ations detected in other medulloblastoma subgroups, particularly
groups 3 and 4 (20). Wnt medulloblastomas also have high levels
of expression of MYC (5). A recent paper showed that mutations
in CTNNB1 disrupt the normal differentiation and migration of
progenitor cells on the dorsal brainstem, resulting in the accumu-
lation of aberrant cell collections, which may relate to their midline
origins (19).
Shh MEDULLOBLASTOMAS
Shh tumors are thought to account for 28% of all medul-
loblastomas (7) (Figure 5). They have an intermediate prog-
nosis between good prognosis Wnt tumors and poor prognosis
group 3 tumors, and may be similar in prognosis to group 4
(5, 20). Shh medulloblastomas show a dichotomous age distri-
bution being more common in both infants (<4 years) and adults
(>16 years) (see Figure 2) (20). Aberrant Shh signaling in nor-
mal human development can cause holoprosencephaly, a disorder
which affects the midline of the face and nervous system, and there
is an increased risk of infant medulloblastoma in Gorlin syndrome,
which have germline mutations in PTCH, the Shh receptors (21).
The sonic hedgehog (Shh) pathway plays a key role in normal
cerebellar development where it induces proliferation of neuronal
precursor cells in the developing cerebellum and other tissues (22).
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FIGURE 4 | Schematic overviewing Wnt signaling.
FIGURE 5 | Schematic overviewing Shh signaling.
The Shh ligand is normally secreted by Purkinje neurons and pro-
motes formation of the external germinal layer from the upper
rhombic lip (21), and Shh tumors are thought to arise from the
granule neuron precursor cells (23).
Desmoplastic/nodular and MBEN are almost exclusively asso-
ciated with Shh pathway activation, although pathway activa-
tion is also observed in classic and large cell/anaplastic tumors
(24, 25). Molecular analysis of sporadic medulloblastomas com-
monly shows Patched-1 (PTCH1) mutations, although mutations
in SMO and Suppressor of Fused (SUFU) have been described
(23–25). All mutations result in over-activation of the Shh signal-
ing pathway. Binding of Shh to its receptor PTCH1 relieves tonic
inhibition of SMO and allows release of the Gli family of tran-
scription factors from inhibitory protein complexes, such as SUFU
(26). Activation of the hedgehog pathway leads to an increase
in Snail protein expression and a resultant decrease in cell–cell
adhesion (26). Hedgehog signaling also appears to be a crucial
regulator of angiogenesis and thus metastasis (27). Interestingly,
there seems to be some overlap between Wnt and Shh signaling
indicating that there may be a common therapeutic target (26,
28–31). Shh have high levels of expression of MYCN (5) Similarly,
both of these subtypes show over-expression of genes involved in
Notch and Platelet-derived Growth Factor (PDGF) signaling (9).
Shh medulloblastomas appear to be almost exclusively associated
with deletions of chromosome 9q, which is also the location of
the PTCH1 gene (9q22) (8). While Shh tumors have been largely
identified using transcriptional profiling, immunohistochemistry
using, SFRP1, GLI1, and GAB1 have been proposed (5, 18).
GROUP 3 MEDULLOBLASTOMAS
Group 3 tumors account for 28% of all medulloblastomas, and
conceptually it may be convenient to consider them as being
associated with MYC amplification (not MYCN) but not exclu-
sively (5, 7, 16, 32). They are currently detected by transcriptional
profiling, although immunohistochemistry for NPR3 has been
proposed (7, 16, 32). They are associated with the worst progno-
sis of all the subgroups and are frequently metastatic (8). Group
3 tumors are found in infants and children but very rarely in
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adults (see Figure 2) (5). Similar to group 4 tumors, relatively lit-
tle is known about the molecular pathogenesis of group 3 tumors
and they are grouped according to similar transcription pro-
files (7). Group 3 medulloblastomas are mostly classic or large
cell/anaplastic morphology (5). MYC amplification appears to be
highly associated with group 3 tumors and is associated with a
worse prognosis (14). It has been proposed that group 3 medul-
loblastomas are further categorized in to 3α and 3β based on the
expression of Myc (5) with 3α tumors have MYC amplification
and hence carry a worse prognosis (5) and 3β not over-expressing
MYC and have a similar prognosis to group 4 tumors – underlying
the fluid nature of these classifications at present (5). There is a
possible role of the developmentally regulated transcription factor
OTX2 in the development of groups 3 and 4 medulloblastomas
(33). Interestingly, OTX2 had been shown to transcriptionally up-
regulate the oncogene Myc (33). 26% of group 3 tumors have
isochromosome 17q, however, group 3 tumors are much more
likely than group 4 tumors to show gain of chromosome 1q and/or
loss of chromosome 5q and chromosome 10q (5).
GROUP 4 MEDULLOBLASTOMAS
Group 4 medulloblastomas are thought to be the most common
“typical” subgroup of medulloblastoma, accounting for around
34% (5), and can be thought of conceptually as being associated
with isochromosome 17q (5). Group 4 medulloblastomas rarely
affect infants (0–3 years) and mainly affect children, with a peak
age of 10 years (see Figure 2) (5). They are also currently detected
by transcriptional profiling, although immunohistochemistry for
KCNA has been proposed and is awaiting validation (5).
Although they frequently metastasize, they still have an inter-
mediate prognosis, compared with the poor prognosis of group
3 (4, 13, 16, 18). The vast majority of group 4 medulloblastomas
have a classic histology, although less frequently they can have a
large cell/anaplastic morphology (5). Almost two-thirds of group
4 medulloblastomas have an isochromosome 17q (i17q) though
occasionally isolated 17p deletions are seen (7, 8). Isochromosome
17q and 17p mutations are also observed in some group 3 medul-
loblastomas though less frequently (5). Group 4 medulloblastomas
are associated with CDK6 and MYCN amplification but minimal
MYC over-expression (8). Interestingly, chromosome X loss is seen
in 80% of females with group 4 medulloblastomas (8) Groups 3
and 4 medulloblastomas have recently been shown to have EZH2
and KDM6A alterations which are involved in histone methylation
(specifically H3K27) (34, 35).
Other histone methylases/acteylases, such as HDAC5, HDAC9,
MLL2, and MLL3, have also been found to be over-expressed
in medulloblastomas, but in these studies the authors did not
investigate their prevalence in individual subgroups (34, 36). Inter-
estingly, the HDAC5 gene locus is located on chromosome 17q,
which is commonly amplified in group 4 tumors (34, 36).
THERAPEUTIC TARGETING OF MEDULLOBLASTOMAS
Current treatment strategies for medulloblastoma are developed
based on the risk stratification and age of the patient (see Table 1).
In all subgroups of patients, surgery is first line treatment, which
aims for maximal tumor resection. Postsurgical treatment is then
varied with high-risk groups receiving higher-dose multimodal
chemotherapy protocols in addition to craniospinal radiation
(2, 37–40). There are substantial concerns, however, over the
long-term neurocognitive sequelae of whole brain radiation on
the developing brain meaning that in patients younger than the
age of 3 years (or sometimes as old as 7 years) craniospinal radi-
ation is often delayed or eliminated (3, 38–44). Many trials are
currently being undertaken, which are aimed at optimizing the
doses and drugs used in chemotherapy regimes in children to
achieve maximum effect, however, these will not be covered in this
review.
TARGETING THE Wnt PATHWAY
In contrast to the Shh pathway, relatively few drugs have been
developed, which specifically target the Wnt pathway. The reason
for this may be the inherent challenges of targeting the Wnt path-
way (20, 45–47). While the Frizzled receptor would make a possi-
ble target, the majority of mutations in medulloblastomas occur
downstream of this by mutations in CTNNB1, which encodes
for β-catenin (20, 48, 49). Recently, a group found a naturally
occurring compound in beetles termed cantharidin (derivative
norcantharidin) which blocked Wnt signaling in vitro and reduced
the size of intracranial tumors in a mouse model in vivo (50).
Cantharidin and norcantharidin are known to inhibit protein
phosphatases 1 and 2A (PP1 and PP2A) (51). It is thought that
PP2A is required for Wnt mediated β-catenin stabilization down-
stream of the Wnt ligand (51). This represents a possible model for
the development of synthetic derivatives although more research
is needed. This may also represent a possible treatment for other
types of medulloblastoma because activated Wnt signals interact
with other signaling pathways (20, 26, 45, 49).
TARGETING THE SONIC HEDGEHOG PATHWAY
Since the discovery of a naturally occurring hedgehog pathway
inhibitor cyclopamine, a number of cyclopamine derivatives have
been developed with increased potency and bioavailability (22,
52–57). Similar to cyclopamine, these drugs act by inhibition of
SMO (23, 57, 58). The most studied of these analogs is Vismodegib
(GDC-0449), however, much of the research have been conducted
in basal cell carcinomas (BCCs) rather than medulloblastomas
because an increased prevalence of BCCs and a similar molecu-
lar pathogenesis (23). Unfortunately, a number of tumors treated
with Vismodegib later acquired resistance by de novo mutations,
specifically D473H point mutations (23). A new drug, Saridegib
(IPI-926), showed decreased drug resistance in mouse models, and
may be of future interest (28). Other SMO inhibitors have been
developed but many of these have not entered clinical trials (23–25,
28, 29, 57–61).
Interestingly, new in vitro studies have highlighted a role for
arsenic compounds in the treatment of hedgehog-driven cancers
through a different method to other drugs (29). Arsenic com-
pounds appear to disrupt tumorigenesis by targeting GLI, which
are hedgehog signaling pathway components downstream of SMO
and PTCH1 and so may be useful in tumors resistant to treatment
with SMO inhibitors (29). Two other drugs, HPI 1 and 4, have also
been found to inhibit proliferation of cerebellar granule neuron
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precursors, which expressed an oncogenic form of SMO that was
resistant to cyclopamine (57).
TARGETING GROUPS 3 AND 4 MEDULLOBLASTOMAS
Owing to the relative paucity of information on the underlying
pathophysiology of groups 3 and 4 medulloblastomas, no specific
treatments have been developed to target them as yet. The histone
methylases EZH2 and KDM6A represent possible future targets
of these subgroups as they appear to be exclusively expressed in
groups 3 and 4 medulloblastomas (34, 35, 61). Similarly, there may
be a role for histone deacetylase inhibitors, considering the possi-
ble amplification of HDAC5 in association with i17q (35). Some
preclinical studies with histone deacetylase inhibitors have already
shown some promise in medulloblastomas in vitro, however, these
were not associated with molecular profiling of the tumors and
identification of subgroups (35).
CONCLUSION
The identification of different molecular pathways involved in the
pathogenesis of medulloblastomas provides exciting new thera-
peutic targets for the development of new drugs with reduced side
effects (62–70). Although this classification provides a simplified
molecular schema for subdividing tumors, it does not take into
account emerging work around molecular heterogeneity within
tumors, which may become increasingly important as different
molecular therapies enter clinical use. Moreover, in the future a
systems biology approach may be relevant when considering these
complex and intercommunicating pathways.
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